A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer
Recruiting now · Phase 1/Phase 2
Conditions studied: Unresectable, Locally Advanced, Metastatic Cancers, Relapsed/Refractory Lymphomas
In brief
This is a multi-center, open-label study to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary activity of REC-1245 administered orally on a once daily (QD) schedule in participants with unresectable, locally advanced, or metastatic solid tumors.
Key facts
- Study ID
- NCT06678659
- Run by
- Recursion Pharmaceuticals Inc.
- People needed
- 170
- Starts
- 2024-11-21
- Expected to finish
- 2028-10-30
- Last updated by the study team
- 2026-05-08
Who can join
Age: 12 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Have histologically-confirmed unresectable, locally advanced, or metastatic select solid tumors or select relapsed / refractory lymphoma
- Have experienced progressive disease, relapsed disease, or be intolerant to at least one established standard systemic anti-cancer treatment for a given tumor type, or have been considered ineligible for standard therapy.
- Eastern cooperative oncology group (ECOG) performance status ≤1; for adolescent participants, Lansky Performance Status Scale or Karnofsky Performance Status Scale score of ≥70.
- Measurable disease at baseline per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 / Lugano criteria and documented by computed tomography (CT) and / or magnetic resonance imaging (MRI)
You may not qualify if…
- Received treatment with another RBM39 degrader
- Clinically significant gastrointestinal (GI) or GI malabsorption
Where it is running
- City of Hope — Duarte, California, United States (enrolling)
- Cleveland Clinic — Cleveland, Ohio, United States (enrolling)
- START Mountain Region — West Valley City, Utah, United States (enrolling)
- Princess Margaret Cancer Centre — Toronto, Ontario, Canada (enrolling)
- McGill University Health Centre (MUHC) - The Montreal — Québec, Canada (enrolling)
- SCRI Oncology Partners - PPDS — Nashville, Tennessee, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.